REG - Crism Therapeutics - Response to Movement in Share Price

CRISM' TherapeuticsAnnouncement

03/07/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240703:nRSC0420Va&default-theme=true

RNS Number : 0420V  Crism Therapeutics Corporation  03 July 2024

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

03 July 2024

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Response to Movement in Share Price

CRISM Therapeutics Corporation ("CRISM" or the "Company") notes the increase
in the Company's share price today and confirms that it is not aware of any
specific reason for the increase. The Company's share price has fallen since
admission to AIM (Admission) on 31 May 2024, and today's price reversal
reflects the Board's underlying view of the value of the business. The Company
continues to work on its stated strategy of submitting a Clinical Trial
Application in the second half of 2024 for its lead product, ChemoSeed. The
Company is also at contract stage to provide services with an early stage UK
SME who are seeking to utilise CRISM's drug formulation expertise. The value
of that contract would be approximately £230k + VAT.  A further announcement
will be made in due course.

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Buchanan
 Andrew Webb, CEO                Richard Morrison

 Chris McConville, CSO           Adam Cowl                         Mark Court mark.court@buchanancomms.co.uk

                                                                   Jamie Hooper jamie.hooper@buchanancomms.co.uk
 via Buchanan                    +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPMSSMFIDELSEFW